- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022;40(10):1051-1058.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11-18.
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: The randomized clinical FinXX trial. JAMA Oncol. 2017;3(6):793-800.
Adjuvant capecitabine in early breast cancer
Key messages
- The capecitabine-containing regimen (docetaxel plus capecitabine-cyclophosphamide and epirubicin plus capecitabine) significantly improved overall survival compared with docetaxel-cyclophosphamide and epirubicin plus fluorouracil during a median patient follow-up time of approximately 15 years.
- The 15-year survival rate was 77.6% in the capecitabine group and 73.3% in the control group.
